Abstract: Opportunistic pathogens exploit diverse strategies to sabotage host defenses.P seudomonas aeruginosa secretes the CFTR inhibitory factor Cif and thus triggers loss of CFTR, an ion channel required for airway mucociliary defense.However, the mechanism of action of Cif has remained unclear.I t catalyzese poxide hydrolysis,b ut there is no knownr ole for natural epoxides in CFTR regulation. It was demonstrated that the hydrolase activity of Cif is strictly required for its effects on CFTR. As mall-molecule inhibitor that protects this key component of the mucociliary defense system was also uncovered. These results provide ab asis for targeting the distinctive virulence chemistry of Cif and suggest an unanticipated role of physiological epoxides in intracellular protein trafficking.
Inpatients with underlying airway disease,i nfection by
Pseudomonas aeruginosa is am ajor cause of morbidity and mortality. [1] While this ubiquitous soil organism is routinely inhaled, the mucociliary elevator efficiently clears it from the airway under normal circumstances.H owever,p ulmonary impairment enables the bacterium to colonize the lung, form biofilms, [2] and trigger recurrent infections and inflammation.
P. aeruginosa is often refractory to antibiotic treatment in patients with cysticf ibrosis (CF) or other airway diseases, leading to chronic and debilitating pulmonary infections and, ultimately,torespiratory failure.Asaresult, there is apressing need for new pathogen-specific therapeutic strategies.W e investigated av irulence factor that allows clinical isolates to sabotage an essential component of the mucociliary clearance machinery,t he CF transmembrane conductance regulator (CFTR). [3] P. aeruginosa secretes an arsenal of toxins and virulence factors that aid the bacterium in airway colonization and persistence. [4] Among them is CFTR inhibitory factor (Cif), the founding member of adistinct class of epoxide hydrolase (EH) enzymes with homologues in several other airway pathogens,i ncluding Acinetobacter and Burkholderia species. [5] Cif is delivered into the cytoplasm of human airway epithelial cells.T here,i tb locks the post-endocytic deubiquitination of CFTR, [6] thereby inducing ar apid drop in apical CFTR and chloride-secretion levels [7] and thus phenocopying key aspects of CF. [8] Cif is am ember of the a/b hydrolase superfamily [7, 9] and catalyzes the hydrolysis of representative epoxides such as epibromohydrin (EBH). However,C if has an on-canonical active site [5a, 10] and neither EH enzymes nor epoxide/diolbased signals are known to regulate protein trafficking. Thus, to rigorously investigate the catalytic machinery of Cif and to assess the possibility of anew physiological role for epoxides, we used our crystal structure [9] to generate ap anel of activesite mutations.According to our model of the Cif mechanism (Figure 1 ), His 177 and Ty r239 position the substrate for hydrolysis and polarize the C À Ob onds for epoxide ringopening, attack by the Asp 129 nucleophile forms ac ovalent Figure 1 . The active site of WT Cif is shown (stick model;PDB entry 3KD2). Based on analogy to other EH enzymes, acandidate mechanism is shown (curved arrows). As described in the text, activesite residues with avariety of proposed catalytic functions were mutated as indicated (straight arrows).
intermediate ( Figure 1, arrow 1) , and the Glu 153/His 297 pair activates aw ater molecule for hydrolytic release of the product ( Figure 1 , arrow 2). His 207 is located in the activesite tunnel. Site-directed Cif mutants were engineered to carry either disruptive (D129S,H177A, Y239F,orH207A) or conservative (E153D) substitutions in one of these key residues.
As predicted, each mutation reduces the hydrolysis of EBH by Cif (Figure 2 , closed bars). TheD129S,H177A, and Y239F mutants lack detectable EBH hydrolysis,whereas the H207A and E153D mutants retain 22 %and 66 %ofwild-type (WT) EH activity,r espectively.N one of these mutations significantly alter the overall structure of Cif.W edetermined the crystal structure of each mutant at aresolution d 2.12 , with stringent coordinate errors 0.2 . Each can be directly superimposed on the WT structure with aC a RMSD value 0.13 ( Figure 2 , inset;T ables S1-S3 in the Supporting Information). Active-site changes are confined to the vicinity of the altered side chain ( Figure S1 in the Supporting Information). Thermal denaturation experiments confirmed the stability of the mutants (Table S4) . Collectively,t he effects of these mutations support our model of Cif catalysis ( Figure 1 ). Thed ata also suggest that His 207 plays ar ole in substrate binding.
With these mutants in hand, we determined whether the ability of Cif to reduce apical CFTR levels is dependent on its EH activity.Wild-type or mutant Cif was applied to polarized human bronchial epithelial cells expressing WT CFTR, and the amount of CFTR at the apical membrane was characterized by surface biotinylation and immunoblotting. Whereas WT Cif triggers as ubstantial loss of apicalmembrane CFTR, none of the mutant Cif proteins mediate as tatistically significant effect (Figure 2 , open bars). The homologous protein from A. nosocomialis (aCif), which also hydrolyzes epoxides and reduces apical CFTR levels, [5a] exhibits asimilar EH dependence ( Figure S2 ).
While Cif may participate in intracellular protein-protein interactions, [6] thestability and external shape of the WT and mutant Cif proteins are essentially indistinguishable,t hus making it unlikely that Cif-protein interactions drive the loss of apical CFTR. Instead, the requirement for EH activity suggests the existence of an epoxide signal involved in the deubiquitination and post-endocytic recyclingo fC FTR, that is,apreviously unknown mammalian epoxide signaling mechanism. Furthermore,s ome mutations exhibit residual hydrolytic activity for epibromohydrin but are unable to trigger robust loss of CFTR. Since our xenobiotic test substrate is much smaller and more hydrophilic than most cellular epoxides, [11] these mutants have presumably selectively lost the ability to hydrolyze the authentic in vivo targets of Cif.
Our results also suggest that Cif-mediated loss of CFTR could be blocked by small-molecule EH inhibitors,several of which have been developed for other EH enzymes. [12] We first surveyed 18 candidates for Cif inhibition by using ar adiolabeled reporter substrate (Table S5 , Figure S3 ). However,this screen identified only weak inhibition (maximum 25 % AE 3% with 100 mm N,N'-di-(3,4-dichlorophenyl) urea (DCPU, 1)), which was limited in part by compound solubility.G iven the stereochemical deviation of the Cif active site compared to previously characterized EHs, [10] we suspected that abroader search of chemical space would be required to identify ap otent Cif inhibitor. Neither of our previously described assays for Cif activity [9] can be readily formatted for highthroughput screening (HTS). Furthermore,ascreen of wellcharacterized 1,2-disubstituted fluorogenic soluble EH reporters showed no activity ( Figure S4 ), which is consistent with the steric constraints of the Cif active site. [9] However, aparallel survey of xenobiotic substrates revealed that Cif can hydrolyze glycidyl methacrylate ( Figure S5 ), the hydrolytic trigger in ac ollection of monosubstituted fluorogenic epoxides that was being developed in parallel for mammalian microsomal EHs. [13] Cif generated ar obust hydrolysis signal with several members of the panel ( Figure S6 ) and showed the highest activity against cyano(6-methoxynaphthalen-2-yl)methyl(oxiran-2-ylmethyl) (CMNGC, 2;F igure 3a).
Using CMNGC as af luorescent reporter and DCPU as apositive control for inhibition, we next screened alibrary of 1,600 compounds, [14] including FDA-approved and orphan drugs ( Figure S7 ). Theprimary assay yielded excellent results, with an average Z' value of 0.82 AE 0.06 (Table S6) , and a2.9 % hit rate (47 compounds) when using a30% inhibition cut-off ( Figure 3b and Table S7 ). Secondary assays (Tables S8 and  S9 ) confirmed one of the two top hits,t he thyroid hormone Figure 2 . Epoxide hydrolysis is necessary but not sufficient to induce CFTR degradation.The EH activity for WT Cif and each mutant was determined using the adrenochromea ssay (closed bars, left-hand axis). The activitieso fCif mutants D129S, Y239F, and H177A were indistinguishable from control (buffer), while Cif mutants H207A and E153D retained residual activity (n = 3, standard deviation (SD)). Apical WT CFTR levels were detected through cell-surface biotinylation of monolayers of polarized bronchial epithelial cells followingtreatment with purified Cif proteins, and the percentage reduction in CFTR was calculated compared to control cells (open bars, right-hand axis). WT Cif, but none of the mutants, triggered significant loss of CFTR (n ! 3, standard error of the mean (SEM)). Inset:C a traces are shown for WT Cif (cyan) and all mutants (gray), followingleast-squares superposition. Mutant side chains are shown as stick models (C = orange). ***, P < 0.001;*,P < 0.05, based on individualcomparisons to control.
. . This chemical tool enabled us to test our hypothesis that aC if inhibitor would protect CFTR in human airway epithelial cells.Control experiments confirmed that tiratricol by itself shows no significant cytotoxicity,d oes not affect bacterial growth rate ( Figure S8 and S9), and has no significant effect on the apical-membrane abundance of CFTR ( Figure 4a ). However,compared to dimethyl sulfoxide (DMSO,v ehicle), tiratricol blocked the ability of either purified Cif protein or co-cultured P. aeruginosa to reduce the levels of apical-membrane CFTR (Figure 4a ). These observations strongly support the importance of EH catalysis in triggering CFTR loss and demonstrate that an inhibitor could provide therapeutic benefit. Since tiratricol inhibits not only purified Cif,but also Cif encapsulated by P. aeruginosa within outer membrane vesicles, [15] the inhibitor appears to be able to access compartments across alipid bilayer.
To evaluate the stereochemistry of tiratricol-mediated inhibition, we also tested the inhibitory potential of six chemical variants.W hile ap ropionate replacement for the acetate moiety yields as imilar IC 50 value (6;T able 1), all other substitutions individually and collectively reduced the potencyofthe scaffold. To explore the stereochemical basis of the observed structure-activity relationships,w ec o-crystallized Cif in complex with tiratricol and determined the structure to 1.75 r esolution (Figure 4b and Table S10 ). Isomorphous difference and anomalous electron density maps clearly reveal the presence of the three tiratricol iodine atoms per Cif protomer (Figure 4b ). Consistent with the substitution data, the R 1 ,R 2 ,a nd R 3 groups are in close contact with the protein surface,w hereas the R 4 acetate moiety protrudes towards the solvent. Thus,s tructural changes at the R 4 position could yield more selective compounds with equal or enhanced potencya gainst Cif and improved pharmacological characteristics.
Tiratricol does not displace the active-site water molecule that occupies the putative site of the substrate epoxide oxygen (Figure 4c ). Instead, it occludes the entrance,w hich is formed by ar ing of hydrophobic residues.I ta lso fills part of av estibule immediately adjacent to the core active-site residues ( Figure 4c ). Together,these observations suggest that tiratricol may not be acting as acompetitive inhibitor,and indeed, kinetic analysis of CMNGC hydrolysis reveals that the substrate concentration has little or no effect on the inhibitory equilibrium binding constant K i (Figure 4d ). Our results suggest that extending the structure of tiratricol to reach the core activesite residues may generate competitive Cif inhibitors with greater potencya nd selectivity.
Cif inhibitors may contribute to successful therapy for the prevention and treatment of pulmonary infections caused by P. aeruginosa.I nc hronic obstructive pulmonary disease (COPD) and pneumonia, where P. aeruginosa infections can lead to high patient morbidity and mortality, [16] Cif could potentially phenocopy CF in patients with WT CFTR, suppressing its apical-membrane levels [8] and thereby hampering mucociliary clearance and facilitating infection. In cystic fibrosis, P. aeruginosa represents the dominant pulmonary pathogen and may be present in up to 97 %o fa dult cases. [17] Thus,a lthough new modulator combinations can modestly restore CFTR function in some CF patients, [18] Cifmediated effects can antagonize their therapeutic efficacy, [19] thereby trapping patients in ad ownward spiral of infection and inflammation. While tiratricol itself causes metabolic complications, [20] the HTS protocol and structural information presented herein provide as trong foundation for identifying and elaborating additional inhibitor chemistries to avoid these complications.Furthermore,broad-spectrum antibiotics can impact important commensal flora. [21] However,C if has au nique active-site geometry shared among homologues found in opportunistic pathogens. [10] As ar esult, its EH activity likely represents ah ighly selective therapeutic target [4] to bolster mucociliary defenses and combat airway infections in vulnerable patients.
Cif also provides important new clues to cellular physiology.A lthough epoxides derived from the arachidonic and Figure 3 . Inhibition of Cif activity.a )HydrolysisofCMNGC by Cif converts the epoxide into avicinal diol, which undergoes achemical rearrangement to release afluorescentp roduct. [13] b) Alibrary of 1,600 molecules was tested for the ability to inhibit Cif-mediatedh ydrolysis of CMNGC.R esults of the primary screen are displayed (gray and colored points), with the average value for the positive control (the inhibitor DCPU) displayed to the right for reference (black, circled). Molecules above a30% inhibition cut-off were retested in asecondary screen, with results encoded by color.The point corresponding to tiratricol is circled.F or details, see Tables S7 and S8. 
Angewandte
Chemie linoleic acid pathways are potent signaling molecules,n one have yet been implicated in protein trafficking or deubiquitination. [22] Our results suggest that abacterial virulence factor can hydrolyze mammalian signaling molecules containing an epoxide functionality,a nd that this activity is required to trigger the degradation of apical-membrane CFTR in human airway epithelial cells.T oo ur knowledge,t his represents the first example of ap athogenic EH that can subvert endogenous mammalian epoxide/diol signaling mechanisms to exert control over host physiological pathways.F urthermore, although epoxides are generated from polyunsaturated fatty acids in all cells,t heir impact on epithelial cells is poorly understood, particularly in comparison to the extensive literature on endothelial and immune responses. [23] Because the effect of Cif can be induced by highly purified protein, our data strongly suggest that at least one epithelial-derived epoxide/diol pair is responsible for the Cif-mediated loss of CFTR. Finally,s ince this process has been shown to involve the blockade of post-endocytic deubiquitination by USP10, our data also provide evidence for regulation of the peripheral protein trafficking machinery by asignaling epoxide.
Experimental Section
See the Supporting Informationfor detailed methods.
Mutagenesis and protein purification:C if mutations were generated by using in vivo yeast recombineering or the QuikChange Mutagenesis Kit (Stratagene), and the Cif proteins were expressed and purified as described previously. [24] Epoxide hydrolasee nzyme assay:T he radioactivity,a drenochrome,a nd fluorogenica ssays were performed as described previously, [9, 13, 25] using tritium labeled cis-stilbene oxide,e pibromohydrin (Sigma),a nd CMNGC (3)a ss ubstrates, respectively.F or assays with CMNGC,m easurements were amde using af luorescent plate reader with l ex = 330 nm and l em = 465 nm.
High-throughput screening:T he primary screen surveyed the Pharmakon 1600 (MicrosourceDiscoverySystems) library [14] at room temperature (ca. 25 8 8C) in 96-well plates,with 25 mm CMNGCasthe fluorogenic reporter substrate,1mm Cif protein, and test compounds at 10 mm or 10 mm DCPU as apositive control. Thefluorescence signal was measured after 60 min. Thes econdary screen was performed at 37 8 8Cand with fluorescence readings made in kinetic mode.
Crystallization, data collection and processing, structurer efinement, and analysis:Cif crystals were obtained by vapor diffusion (see Table S1 for composition) and flash cooled. Data were collected and processed,a nd structures determined, refined, and visualized as described. [9, 24] Forc o-crystallization, solutions were supplemented with 200 mm tiratricol and 0.2 %( v/v)D MSO.S tructuresh ave been deposited in the PDB (see Tables S2 and S10 for PBD IDs).
Cell culture:Parental human bronchial epithelial CFBE41o-cells stably transduced with WT CFTR (CFBE cells) [26] were cultured essentially as described, [8] with modifications as described in the Supporting Information.
Determination of apical-membrane levels of CFTR:P olarized monolayers of CFBE cells were treated apically with 50 mgofpurified Cif protein, P. aeruginosa,orbuffer or medium control, and incubated for 1h at 37 8 8Ci na5% CO 2 incubator. Ther elative abundance of CFTR was then determined by surface biotinylation as described previously. [27] Results are shown as an average of independent experiments performed am inimum of three times on separate days and with different passages of cells.
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DETAILED METHODS
Mutagenesis and protein purification. The Cif-D129S and Cif-E153D mutations were generated using an in vivo yeast recombineering technique as previously described.
[1] The Cif-H177A, Cif-Y239F and Cif-H207A mutations were generated by altering the coding sequence of the Cif-WT expression plasmid pDPM73
[1b] using the QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene). Carboxy-terminal hexahistidine tagged Cif protein was expressed in Top10 Escherichia coli (Invitrogen) cells and purified by immobilized metal affinity chromatography (IMAC) as described previously in detail. [2] Purified Cif protein was dialyzed into 100 mM NaCl, 20 mM sodium phosphate (pH 7.4) for biochemical and functional assays, or 100 mM NaCl, 20 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (pH 7.4) for crystallography.
Circular dichroism spectroscopy.
Circular dichroism (CD) spectra were determined for 10 µM solutions of Cif protein. Variable wavelength CD spectra were first measured at 20°C. Next, the thermal denaturation of each protein was monitored by observing the CD signals at 208, 215, and 222 nm wavelengths and increasing the temperature of the protein by 1°C per measurement.
Epoxide hydrolase enzyme assay. The radioactivity assay was carried out using tritium labeled cis-stilbene oxide as the substrate as described previously in detail. [3] The adrenochrome reporter assay was performed as described previously [4] using epibromohydrin (Sigma) as the substrate. We define 1 unit (U) of activity as 1 µmol of substrate hydrolyzed per minute. All assays with fluorogenic reporter substrates were carried out as described previously. [5] Buffers included 0.1 mg/ml bovine serum albumin. For assays using CMNGC (3) as the fluorogenic substrate, measurements were taken using a fluorescent plate reader with λ ex = 330 nm and λ em = 465 nm.
High-throughput screening.
All high-throughput screening assays were performed using 96-well plates, a 200 µL reaction volume, and a fluorescent plate reader. The primary screen surveyed the Pharmakon 1600 (Microsource Discovery Systems) library. [6] It was carried out at room temperature (~25 °C) using 25 µM CMNGC as the fluorogenic reporter substrate, 1 µM Cif protein, test compounds at 10 µM, and 10 µM DCPU as a positive control for Cif inhibition. The fluorescent signal was measured after allowing the enzyme reaction to proceed for 60 min. The secondary screen was performed at 37 °C using the same conditions as the primary screen, except that fluorescent readings were taken in kinetic mode (every minute for the 60 min reaction).
Crystallization, data collection and processing, structure refinement, and analysis. Cif crystals were obtained by vapor diffusion against 400 µL of reservoir solution in a 4 µL hanging drop at 291 K. [2,4a] The Cif protein solution was mixed in a 1:1 ratio with reservoir solution (see Table S1 for composition). Prior to data collection, crystals were washed in cryoprotectant solution, which consisted of the same recipe as the well solution supplemented with 20% (w/v) glycerol, and flash cooled by plunging into a liquid nitrogen bath. For co-crystallization of Cif with tiratricol, all solutions were supplemented with 200 µM tiratricol and 0.2% (v/v) DMSO. Oscillation data were collected at 100 K at the X6A beamline of the National Synchrotron Light Source at Brookhaven National Laboratory. Diffraction images were processed and scaled with the XDS package. [7] Molecular replacement (using apo-Cif-WT as the search model, PDB ID 3KD2) and iterative rounds of automated refinement were carried out with Phenix. [8] WinCoot [9] was used for manual adjustment of the model, and PyMOL [10] was used to generate images of the final models.
Coordinates and structure factors have been deposited in the Protein Data Bank with the following entries: 4DLN (Cif-D129S), 4DMH (Cif-H207A), 4DMF (Cif-H177A), 4DMK (Cif-Y239F), 4DM7 (Cif-E153D), and 4YX9 (Cif:tiratricol complex).
Cell culture.
Parental human bronchial epithelial CFBE41o-cells stably transduced with WT-CFTR (CFBE cells) [11] were cultured essentially as previously described. [12] Minimal essential medium (Invitrogen) was supplemented with 50 U/mL penicillin (Sigma), 50 µg/mL streptomycin (Sigma), 2 mM L-glutamine (Cellgro), 9.1% [v/v] fetal bovine serum, 0.5 µg/mL puromycin (InvivoGen), and 5 µg/mL Plasmocin (InvivoGen ). Cells were grown at 37 °C with 5 % CO 2 . To establish polarized monolayers, 1·10 6 cells were seeded onto 24 mm Transwell permeable supports (0.4 µm pore size; Corning) and grown in an air-liquid interface culture at 37 °C with 5 % CO 2 for 6-9 days prior to use.
Determination of apical-membrane levels of CFTR.
Polarized monolayers of CFBE cells were treated apically with 50 µg of purified Cif protein, P. aeruginosa, or a buffer or medium control, and incubated for 1 hr at 37°C in a 5 % CO 2 incubator. The relative abundance of CFTR was then determined by biotinylating apical membrane proteins, capturing the surface pool with immobilized streptavidin resin following cell lysis, and probing for WT-CFTR by Western blot as described previously in detail. [13] Results are shown as an average of independent experiments performed a minimum of three times on separate days and with different passages of cells. In each case, the main chain is shown as thin lines and the side chains of the matched mutated and WT residues are highlighted in bold. The WT protein is shown in green, the Asp129 nucleophile mutant in yellow, the Glu153 charge relay mutant in cyan, the ringopening His177 and Tyr239 mutants in magenta, and the substrate His207 mutant in gray. Where applicable, hydrogen bonds are color coded to match the protein structure they are derived from. All waters are displayed as red spheres. Non-carbon atoms are colored based on identity (O=red, N=blue). Figure S2 . Reduction of apical CFTR by the Cif homolog from Acinetobacter nosocomialis (aCif) requires EH activity. Sequence and structure alignments identified Asp158 as the active-site nucleophile required for epoxide hydrolysis by aCif, a Cif homolog that also triggers the degradation of CFTR in airway epithelial cells. [14] As shown here, the catalytically inactive aCif-D158S mutant lacks the ability to trigger WT-CFTR degradation in polarized CFBE airway epithelial cells, as assessed by cell-surface biotinylation and immunoblotting. Values are reported relative to control cells exposed to buffer only (n=3). *, P < 0.01. Figure S3 . Results of a preliminary radioactivity-based screen for a Cif inhibitor. The assay, performed in triplicate using 50 µM CSO as a substrate, was used to screen for Cif inhibition by a limited library of 18 compounds selected based on their ability to inhibit other EHs and on known Cif substrate preferences. [4a] For compound identities, see numbering in Table S5 . (A) The initial screen was performed using 2 µM Cif protein incubated for 1 hr at 37°C with 100 µM test compound. (B) Compounds chosen for an additional screen were assayed for Cif inhibition using 1 µM Cif protein incubated for 2 hr at 37°C with 100 µM test compound. Figure S4 . Fluorogenic sEH substrates are not hydrolyzed by Cif. Fluorogenic substrates for soluble EH (sEH) were incubated with buffer (blue), Cif (color-coded by concentration) or murine sEH (red) at 37°C. Epoxide hydrolysis was assayed via generation of fluorescent product as a function of time using a fluorescent plate reader with λ ex = 330 nm and λ em = 465 nm. Figure S5 . Cif hydrolyzes monosubstituted epoxides found in a series of mEH fluorogenic reporter substrates. Specific activity was determined as previously described. [14] One unit (U) is equal to µmoles hydrolyzed per minute. n ≥ 3, error bars = SEM. Cultures were grown at 37ºC with shaking, and culture density was determined by measuring the nominal absorbance at 600 nm (A 600 ) every fifteen minutes. The cultures exhibit indistinguishable growth rates. n = 3, error bars = SD. Figure S9 . Tiratricol causes no significant epithelial cell cytotoxicity under treatment conditions. Cytoxicity was quantified using CFBE cells and the Cytotox 96 non-radioactive cytotoxicity assay (Promega). Monolayers were seeded at 10 4 cells/well in 96-well plates, cultured for four days, and then treated with medium (control), 0.1% (v/v) DMSO, 100 µM tiratricol, or 0.1% (v/v) Triton X-100 for 6 hours. Data were evaluated using a one-way ANOVA with Tukey's Honestly Significant Differences multiple comparisons test. Neither treatment was significantly different from medium or from each other (n.s.; P > 0.05). For display, A 490 values were corrected by subtraction of the corresponding value for negative control treatment (medium) and normalized to yield 100% toxicity for the positive control treatment (0.1% Triton-X100). n ≥ 3, error bars = SEM. (Figure 1 ) assume a stable globular fold in solution. Additionally, it was unclear if the Cif mutants would retain their native structure at the assay temperature of 37°C. To examine this, we performed thermal denaturation of wild type and mutant Cif proteins and monitored the secondary structural elements by circular dichroism (CD) spectroscopy.
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For each variant of the Cif protein, denaturation occurred at ≥ 49.6°C. For each sample, there were no detectable changes to the protein's secondary structure at 37°C. Therefore, we conclude that each Cif mutation has little or no effect on the thermal stability of the protein. Numbers correspond to the data shown in Figure S3 . [16] a S/B = signal-to-background ratio b S/N = signal-to-noise ratio c Z' is a statistical parameter indicative of assay robustness and reproducibility d %I = percent of the total enzyme activity inhibited e SD = standard deviation f Z = screening window coefficient [16] a S/B = signal-to-background ratio b S/N = signal-to-noise ratio c Z' is a statistical parameter indicative of assay robustness and reproducibility d SD = standard deviation 
